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Abstract  
Purpose: To assess the long-term patient reported outcomes following TO-TVT as a 
secondary continence procedure in women with recurrent stress urinary incontinence (R-
SUI). 
Methods: A secondary analysis of the 9-years follow-up of the E-TOT study: 341 women 
with predominant SUI symptoms were randomised to undergo either inside-out or outside-in 
TO-TVT between April 2005 and April 2007. 46 women had R-SUI following previously 
failed continence surgery and are the basis of this analysis as a one single cohort. Primary 
outcome was the patient-reported success rate defined as Very/Much improved on Patient’s 
Global Impression of Improvement (PGI-I). Secondary outcomes included late adverse 
events; impact on women’s quality of life and sexual function. Statistical analysis was 
performed using SPSS v.23.  
Results: 63% completed the 9-year follow-up. The success, based on the PGI-I was 62.1% 
with no significant difference between groups (OR: 5.33; 95%CI: 1.03, 27.76; p=0.094). 
Clinically significant improvement in QoL was found in 84.2%. Adverse events included 
vaginal erosions (n=3) and groin pain (n=2). The small sample size is a limitation in this 
study nevertheless this is one of the largest cohorts reported for women with R-SUI and the 
first to report the long-term outcomes of TO-TVT as a secondary continence procedure. 
Conclusions: TO-TVT operations are associated with good patient-reported success rates 
(62%) in women with previous failed continence surgery up-to 9-years. There is a non-
significant trend towards better outcomes with the Inside-out TO-TVT. 
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Introduction   
 
In the UK, the lifetime risk of women undergoing surgery for stress urinary incontinence 
(SUI) is 3.6% [1]. The reoperation rate for recurrent SUI (R-SUI) varies between studies 
(8.8% – 17%)[2, 3]. The median time to undergo repeat continence surgery for R-SUI in the 
UK is 2.8 years[4].  
 
Management of R-SUI can be challenging being dependent on multiple factors such as: the 
type of the index procedure, time-to-failure, and patients’ factors such as BMI, co-
morbidities, and patient’s attitude towards further surgery. Surgeons and institution factors 
are also important such as the availability of surgical expertise and specific investigations 
(video-urodynamics (VUD), urethral pressure profile (UPP). The Society of Obstetricians and 
Gynaecologists of Canada recommends the use of conservative management, such as pelvic 
floor muscle training(PFMT), as a first line treatment in women with R-SUI[5]. There is no 
consensus on the best surgical management of R-SUI and a number of options have been 
suggested including midurethral tension-free vaginal slings(MUS) including retropubic 
tension-free vaginal tape(RP-TVT) and transobturator tension-free vaginal tape (TO-TVT) 
and more traditional procedures such as colposuspension(CS) and autologous fascial 
slings(AFS)[6]. 
 
A systematic review and meta-analysis in 2013 showed that RP-TVT and TO-TVT were 
similarly effective in the surgical treatment of women with R-SUI however the authors urged 
caution in interpretation of the results due to the relatively small number of patients  (n=350) 
and the limited follow-up period (18 month)[4].  
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There is a paucity of data on the long-term outcomes of TO-TVT especially as a secondary 
continence procedure in women with R-SUI. In the UK, the National Institute for Health and 
Clinical Excellence(NICE), the Cochrane review in 2015 and most recently the European 
review(SCENIHR) on surgical meshes in urogynaecological surgery[7-9] have all highlighted 
the lack of long-term outcomes data for TO-TVT. This study aim to assess the long-term 
patient reported outcomes in a cohort of women undergoing TO-TVT as a secondary 
continence procedure within the E-TOT randomised controlled trial (RCT)[10, 11]. We have 
previously reported the 1-year outcomes in this cohort showing patient-reported success rate 
of 70% [12].  
 
Materials and Methods 
A secondary analysis of the E-TOT RCT, performed in a UK tertiary urogynaecological 
centre in the period of April 2005 to April 2007. Ethical approval was obtained for the long-
term follow-up. In the E-TOT study, 341 women were randomly assigned to undergo either 
Outside-in TOT-ARIS® (Coloplast Corp., Minneapolis, MN, USA) or Inside-out TVT-OPTMP 
(Ethicon Inc., Somerville, NJ, USA). The procedures were performed under general 
anaesthesia as originally described by Delorme and de-Leval in 2001 and 2003 
respectively[13, 14]. The women were included in the E-TOT study if they had urodynamic 
SUI or mixed UI with predominantly bothersome SUI symptoms, and had declined or failed 
pelvic floor muscle training. Exclusion criteria included concomitant surgery; uterovaginal 
prolapse (POPQ score ≥2); predominant OAB symptoms, and neurologic conditions such as 
multiple sclerosis.  
 
46 women with R-SUI following previous failed continence surgery at time of randomisation 
were identified and are the basis of this secondary analysis as one single cohort.  
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Pre-operative assessment included a detailed history, pelvic examination and urodynamic 
assessment and completion of symptom severity and QoL questionnaires: King’s Health 
Questionnaire (KHQ)[15]; Birmingham Bowel and Urinary Symptom Questionnaire-
22(BBUSQ-22)[16] and Pelvic Organ Prolapse/Incontinence Sexual Function 
Questionnaire(PISQ-12)[17]. Post-operative assessment at the 1-, 3- and 9-years follow-up 
included, in-addition to the above questionnaires, the Patient Global Impression of 
Improvement(PGI-I)[18], International Consultation on Incontinence Questionnaire–Short 
form(ICIQ-SF)[19], and further questions on adverse events (AEs) and further continence 
surgery.  
 
The primary outcome measured was the patient-reported success rate defined as “very much 
improved” or “much improved” on the PGI-I, with all other responses classified as failures. 
Participants who received further continence surgery during the follow-up period were 
considered as failures. Secondary outcomes included improvement in QoL (≥18 points 
improvement in KHQ score) [20], impact on sexual function (change in PISQ-12 score), and 
late AEs (such as groin/thigh pain and tape erosions). In-addition, we compared these 
outcomes between groups. 
 
Statistical analysis was performed using SPSS version 23. Chi-squared or Fisher’s exact tests 
were used to compare categorical variables. Within-group comparison of KHQ scores and 
PISQ-12 scores were analysed using the Wilcoxon signed rank test while between-group 
comparison were analysed using the Mann-Whitney U test. The results of the PGI-I at 9-year 
follow-up were compared to that of 3-year and 1-year follow-up using McNemar’s test, at the 
Bonferroni corrected significant level of 0.025. All other statistical analyses were performed 
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at 5% significance level in a similar plan to that carried out at 1 and 3 years. We present 
intention to treat (ITT) and ITT considering women who received further continence surgery 
as failures. 
 
Results 
29/46 women completed the follow-up at 9 years, yielding a response rate (RR) of 63.0%. 
The CONSORT diagram shows the recruitment and follow-up data up to the 9-year follow-
up for this subgroup(Figure-1). The participants’ baseline characteristics did not show 
significant differences between groups(Table-1).  
 
- Patient-reported success rate: 
The patient reported success for the whole cohort, based on the PGI-I and considering 
participants who had further continence surgery within the follow-up period as failures, was 
62.1%. There was a non-significant trend, towards better outcomes in the inside-out TO-TVT 
group (Inside-out 80.0% Vs. Outside-in 42.9%, OR:5.33;95%CI:1.03, 27.76, p=0.094) Table-
2. 
 
Compared to the patient-reported success rate in women undergoing “primary continence 
surgery” within the same cohort of the E-TOT study [21], there was a non-significant trend to 
lower success rate in women with R-SUI (62.1% vs 73.2%, OR0.60;95%CI 0.26,1.36, 
p=0.266). 
 
There was a non-significant trend towards drop in the patient-reported success rate over the 
years(Figure-2). Comparison of the patient-reported success, and using Bonferroni corrected 
significance level of p≤0.025, showed non-significant reduction with time: 1vs 9-years and 
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3vs 9-years were 69.6%vs.62.1%, p=0.289 and 66.7%vs.62.1%; p=0.999 respectively. The 
drop in the success rate was not evident in the inside-out group and this triggered a closer 
look and sensitivity analysis.  Using last observation carried forward (LOCF) for participants 
with missing outcomes at 9-years; the patient reported success rate for the whole cohort was 
almost the same (61%) however the success rate of the inside-out group was considerably 
lower (68% vs 80%)(Table-2).  
 
- Late adverse events:  
Pain/ discomfort was reported by 2-participants (both had colposuspension as their index 
surgery): one participant in the outside-in group, with un-successful outcome (“same” on 
PGI-I) reported: “groin pain but not sure if related to the procedure”. The other participant 
was in the inside-out group and reported successful outcome (“much improved” on PGI-I) 
and chronic right side “back pain” since the operation which affects her day to day activities.  
 
Three participants reported receiving diagnosis and/or treatment of tape erosion/ extrusion at 
9-years follow-up; all were in the outside-in group and received surgical excision of the 
eroded portion of the tape. In 2-participants the index surgery was colposuspension and both 
had un-successful outcome following TO-TVT within the E-TOT study and subsequently 
underwent further continence procedures. For the third participant, TO-TVT was also the 
index procedure and despite surgical excision of eroded part of the tape, she continued to 
have successful outcome (“Very Much Improved” on PGI-I) at 9-years.  
 
- Impact on QoL   
19 women (65.5%) completed the KHQ questionnaire at the 9-year follow-up. There were 
statistically significant improvements in all domains of the KHQ compared to baseline, with 
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the exception of general health domain (Table-3). There was a clinically significant 
improvement in QoL (≥18 point improvement in total KHQ score from baseline) in 84.2% of 
the women (Outside-in 80.0%% vs Inside-out 88.9%, OR 2.00, 95% CI 0.15 to 26.73, 
p>0.999). The result pertained on repeating the analysis based on the ≥10 point improvement 
score, which was used for analysis at the 1-year follow-up[12]. 
 
- Sexual Function 
Only 8 women (27.6%) completed the PISQ-12 pre-operatively and at 9-year follow-up. The 
total PISQ-12 score improved in 62.5% (n=5) and deteriorated in 37.5% (n=3) (Table-3).  
 
 
Discussion  
This is the first clinical trial to report on the long-term outcomes of TO-TVT as a secondary 
continence procedure in the management of R-SUI in women. Despite the relatively small 
sample size, it’s the one of the largest cohorts exploring the outcomes of TO-TVT as a 
secondary continence procedure and the first to report the long-term outcomes.  
 
Our results showed a patient-reported success of 62.1% at a median of 9-years follow-up; the 
success rate pertained on sensitivity analysis using LOCF.     
 
We used the PGI-I as the primary outcome as it provides a robust validated and more global 
review of the treatment outcome and is more encompassing of the range of benefits and 
potential harm[23]. We considered women who had any outcome apart from “very/much 
improved” as un-successful to avoid overestimation of the success rate. The success rate in 
our study was higher than a recent systematic review by Nikolopoulos et al[24], they reported 
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that the overall pooled success rates for TO-TVT following previous failed MUS was 55.4% 
(31/56) compared to 72.8% (174/239) for RP-TVT.  A significant limitation in the latter 
review was the large variation in the duration of the follow-up which ranged from 15 to 42 
months.  
 
The 2015 Cochrane systematic review of MUS[8] highlighted the trend towards drop in the 
patient-reported success rate over time for all types of continence surgery. Similar trend was 
seen in our study (69.6% at 1-year vs 62.1% at 9-years). Interestingly this trend was not seen 
in women within the inside-out TO-TVT group except after sensitivity analysis. The sizeable 
and differential fall in the participants’ response rate overtime in the inside-out group 
triggered a closer look by our team. This revealed that a significant percentage of women 
with unsuccessful outcome at 3-years failed to respond at 9-years. This highlights the 
importance of sensitivity analysis, using different assumptions for those with missing 
outcomes, to improve the confidence in the results of long-term follow-up clinical trials.  
 
Compared to TO-TVT as “primary continence surgery”[21] there was a clear trend towards 
lower patient-reported success in women undergoing TO-TVT as a secondary procedure. 
This trend failed to reach statistical significance which may be due to type-2 error secondary 
to the relatively small sample size. Our results are consistent with Stav et al[25] who assessed 
77 women with repeat MUS surgery and a minimum follow-up of 4-years; the patient-
reported success rate was 86% and 62% for primary and repeat MUS respectively (p<0 .001). 
 
Our results at 1 and 9-years showed a clear, though non-significant, trend towards higher 
patient-reported success rate in the inside-out group. The trend pertained on sensitivity 
analysis using LOCF but did not reach statistical significance presumably due to the small 
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size cohort.  This finding is difficult to explain as the surgeons within the E-TOT study were 
quite experienced in both techniques of TO-TVT, the baseline patients’ characteristics were 
not statistically different and the procedures are fairly similar.  A possible explanation for the 
higher success rate in the “inside-out” route would be the limited dissection behind the 
inferior pubic ramus which may contribute to better fixing of the tape in position and 
consequent better urethral support and long-term resilience of the procedure.   
 
Little is known on the long-term AE of TO-TVT as a secondary continence procedure. Ford 
et al[8] reported low rates of groin pain following MUS, mostly were short-lasting and 
resolving within 6 months after the operation. It is therefore an important finding that 2-
participants in our study reported pain/discomfort at the 9-year follow-up. We acknowledge 
the limitation of the data on pain as there is uncertainty on its relation to the procedure 
especially with the lack of control group without surgery. Nevertheless chronic groin pain is a 
known complication for TO-TVT; Teo et al[26] reported 26% leg pain in the immediate 
postoperative period and Zhang et al[27] reported 6.4% groin pain at 7-years following 
inside-out TO-TVT.  
 
In this cohort, the rate of the vaginal tape erosion with TO-TVT as secondary continence 
procedures is relatively high in contrast to the rate of (24:1000) from the Cochrane review by 
Ford et al. Participants reported if they have been diagnosed with tape erosion, and treatment 
received if any, hence the reported rate excludes asymptomatic tape erosions. This is an 
interesting finding that was not previously reported in the literature; The index surgery in 2/3 
participants was colposuspension hence an index “tape” surgery and consequent fibrosis 
could not be blamed for this relatively high erosion rate. The relatively high AE rate in this 
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special cohort of women could not be generalised for women undergoing TO-TVT as 
primary procedures.  
 
Our study is the first to assess the long-term QoL and sexual function in women who 
underwent TO-TVT as secondary continence surgery however the small sample size is a 
limitation. QoL and sexual function are usually difficult to address at long-term follow-up as 
many confounding factors may affect the results such as age, change in patients’ priorities, 
and developing other health conditions. For sexual function, there are more confounding 
factors including vaginal dryness, development of prolapse and even partner-related problems 
can affect the PISQ-12 scores.  We previously reported that 76% of women showed clinically 
improvement in QoL based on the ≥10 point improvement in KHQ score at 1-year follow-up. 
At 9-year follow-up, we used the relatively newer cut-off value of ≥18 point improvement for 
clinically significant improvement[20] and the original cut-off value of ≥10 point [28]. Both 
showed similar results with the majority of women (84%) reporting improvement in their 
QoL.  The sexual function questionnaire could only be assessed in 8-women in our study 
which is too small to draw a meaningful conclusion. Nevertheless there was a trend for two 
third of women to report improvement in their sexual function while one third reported 
deterioration. Zhang et al. reported similar results for sexual function in women treated with 
TO-TVT procedure at 7-years follow-up[27]. 
 
Our results are consistent with the literature on MUS in women with previous continence 
surgery however it’s obviously debatable if 62% long-term success rate is acceptable. There 
is paucity in the literature that can guide us on how to improve the outcome of surgery in this 
special cohort of women; this is further complicated by the lack of understanding for the 
aetiology of R-SUI. The Cochrane review previously showed the lack of data to recommend 
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any of the different management strategies for R-SUI after failed MUS[22]. In a multivariate 
analysis, we have previously shown MUCP <30cmH2O to be the only independent risk 
factor for failure of TO-TVT as secondary continence procedure (OR 9.206, 
95%CI1.511,56.104)[12] Liapis et al [29]P Phowever showed that low-MUCP did not affect the 
success rates of repeat RP-TVT while a combination of low-MUCP and limited urethral 
mobility were associated with significantly reduced success rate.  
Nevertheless, pre-operative urodynamics is mandatory prior to embarking on a repeat 
continence procedure with the aim to ascertain the diagnosis. Special tests such as VUD and 
UPP can be helpful in choosing the correct subsequent procedure[6]. The authors recommend 
that secondary continence procedures should only be performed in tertiary centres with 
expertise in assessment and management of these patients.  These centres should collaborate 
in sharing their data and in well-designed clinical trials to assess the most effective 
investigations and management strategies.  
 
 
- Strengths and limitations:  
This is the first clinical trial to report on the long-term outcomes of TO-TVT as a secondary 
continence procedure. The trend towards better patient-reported outcomes with the inside-out 
TO-TVT is a novel and important finding.  
 
There was no risk of assessor bias in this study, as the 9-year follow-up was done through a 
postal questionnaire and all the outcomes were assessed using validated questionnaires. 
However, the study has its limitations, the relatively small cohort size which is a limitation in 
any study reporting on surgical treatment for women with R-SUI due to relative rarity of the 
disease. This is especially relevant to between-group comparisons in this study with 
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possibility of type-2 error. In-addition, there was a differential loss to follow-up in one group, 
despite our attempts to minimise attrition; this was overcome by sensitivity analysis.  
 
Conclusion:  
TO-TVT operations are associated with good patient-reported success rate (62%) in women 
with previous failed continence surgery up-to 9-years. There is a non-significant trend 
towards better outcomes with the Inside-out TO-TVT. 
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 Figure legends 
Figure 1:  CONSORT diagram of patients recruited and follow-up  
Figure 2: Graph showing the PGI-I success rate at 1-year, 3-year and 9-year follow-
up 
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Figure 2 
Total
Outside-in
Inside-out
Table 1 Baseline characteristics of patients 
 Whole cohort 
n=29  
Outside-in 
n=14 
Inside-out 
n=15 
p-value 
Mean age ± SD 55.62 ± 9.673 58.98 ± 9.946 52.46 ± 8.562 0.069 
Mean BMI ± SD 28.72 ± 4.765 29.86 ± 5.709 27.67 ± 3.559 0.232 
     
Mixed Incontinence 
(MUI) 
6 (20.7%)  3 (21.4%)  3 (20.0%) 0.639 
MUCP <30 Cm H20  7 (24.1%)  4 (28.6%) 3 (20.0%) 0.458 
     
Previous 
hysterectomy 
14 (48.3%) 8 (57.1%) 6 (40.0%) 0.581 
Previous anterior 
repair 
1 (3.4%) 1 (7.1%) 0 (0%) 0.483 
Previous incontinence surgery 
Colposuspension 11 (37.9%) 6 (42.9%) 5 (33.3%) 0.885 
RP-TVT 13 (44.8%) 6 (42.9%) 7 (46.7%) >0.999 
TO-TVT 5 (17.2%) 2 (14.3%) 3 (20.0%) >0.999 
  
MUCP = Maximum Urethral Closure Pressure 
BMI= Body Mass Index 
 
 
 
 
 
 
Table 2: Patient-reported success at 9-year follow-up & Sensitivity analysis  
 Total 
number (%) 
Outside-in 
(%) 
Inside-out 
(%) 
OR (95% CI) p-
value 
PGI-IP * 20/29 (69.0) 8/14 (57.1) 12/15 (80.0) 3.00 (0.58 ,15.61) 0.245 
PGI-IP # 18/29 (62.1) 6/14 (42.9) 12/15 (80.0) 5.33 (1.03, 27.76) 0.094 
Sensitivity analysis based on PGI-I P#P for patients lost to follow-up: 
Assume all missing 
data as failure  
18/46 (39.1) 6/18 (33.3) 12/28 (42.9) 1.50 (0.44, 5.15) 0.737 
Last observation 
carried forward  
28/46(60.9) 9/18 (50.0) 19/28 (67.9) 2.1 (0.63, 7.13) 0.367 
 
P
 
P GI-I success defined as “very much” or “much improved” 
P
*
P Intention-to-treat analysis (ITT) 
P
# 
PIntention-to-treat analysis (ITT) considering women who had further continence surgery as failures  
 
 
  
Table 3: Comparison of KHQ and PISQ-12 scores between pre-operative and 9-year 
follow-up and between Outside-in and Inside-out procedures  
 Median (IQR) p-value Median difference (IQR) p-value 
Pre-op 9-year post op Outside-in Inside-out 
KHQ 
domains 
General health 25.00 
(25.00,37.50) 
25.00 
(6.25,50.0) 
>0.999 0.00 
(0.00 , 0.00) 
0.00 
(-12.50,12.50) 
>0.999 
Incontinence 
impact 
100.00  
(100.0,100.0) 
33.33 
(0.00,50.0) 
<0.001 33.33 
(0.00,66.67) 
83.33 
(41.67,100.0) 
0.085 
Role limitation 83.33  
(58.33,100.0) 
8.33 
(0.00,50.0) 
0.001 33.33 
(16.67,100.0) 
66.67 
(0.00, 91.67) 
0.930 
Physical 
limitation 
66.67 
(50.00,100.0) 
16.67 
(0.00,33.33) 
<0.001 41.67 
(12.50 87.50) 
50.00 
(8.33 , 66.67) 
0.975 
Social 
limitation 
55.56 
(33.33,72.22) 
0.00 
(0.00,11.11) 
0.002 33.33 
(0.00,100.0) 
50.00 
(11.11 , 75.00) 
0.926 
Personal 
limitation 
33.33 
(0.00 , 75.00) 
0.00 
(0.00,33.33) 
0.008 33.33 
(-16.67,66.67) 
18.83 
(6.75 , 45.50) 
0.887 
Emotions 77.78 
(61.11,100.0) 
0.00  
(0.00,44.44) 
<0.001 44.44 
(0.00 , 77.78) 
77.78 
(16.67 , 88.89) 
0.365 
Sleep/ energy 66.67 
(33.33,83.33) 
33.33 
(0.00,62.50) 
0.005 33.33 
(-16.67,50.0) 
16.67 
(0.00 , 58.33) 
0.792 
Severity 
measure 
91.67 
(66.67,100.0) 
25.00 
(0.00,75.00) 
0.001 58.33 
(-8.33, 75.00) 
54.17 
(4.17 , 93.75) 
0.757 
Total KHQ 66.36 
(56.42,76.52) 
16.67 
(2.78,23.46) 
<0.001 30.86 
(13.81,68.52) 
54.51 
(23.61 , 64.85) 
0.806 
Total PISQ-12 33.50 
(24.00,36.00) 
35.00 
(27.00,37.00) 
0.575 3.00 
(-4.25 , 9.50) 
-0.50 
(-6.50 , 11.50) 
0.663 
 
 
